Figure 5 | Leukemia

Figure 5

From: RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Figure 5

The MEK inhibitor trametinib effectively kills RAS mutant primary BCP-ALL cells. (a) Sensitivity towards the MEK inhibitor trametinib in primary or xenograft-derived BCP-ALL cells. Mean and standard deviation are shown. (b) Relative cell survival at 0.14 μm trametinib split up per case. Gray circles represent wild-type cases; red triangles represent RAS pathway mutant cases. Bars represent group mean. Groups were compared by Mann–Whitney U-test, ***P=0.001. (c) Western blot analysis of phospho-ERK (T202/T204) and phospho-MEK (S217/S221) in a subset of samples tested in (a). †Sample isolated after thawing, cells previously tested positive. (d) Ex vivo response to trametinib (left panels) and sensitization towards prednisolone (right panels) in one NRAS G12D-mutant and one RAS pathway wild-type case.

Back to article page